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Introduction
The recent pandemic of  coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2), has resulted in millions of  infections and more than 1 million 
deaths globally in a remarkably short period (1). Although most human coronavirus infections cause mild 
respiratory disease, SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) resulted 
in fatality rates of  10% and 36%, respectively (2, 3). Although the precise death counts remain unclear for 
SARS-CoV-2, fatality rates appear to be lower than those of  SARS-CoV and MERS (4). But its alarming 
rates of  spread, linked to transmission during the asymptomatic stage of  infection, render this pathogen 
particularly lethal. Although the development of  vaccines against SARS-CoV-2 are underway, therapeutics 
are urgently needed to support those with more severe infection. Among the therapeutics, several antivirals 
The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), coupled with 
a lack of therapeutics, has paralyzed the globe. Although significant effort has been invested in 
identifying antibodies that block infection, the ability of antibodies to target infected cells through 
Fc interactions may be vital to eliminate the virus. To explore the role of Fc activity in SARS-CoV-2 
immunity, the functional potential of a cross–SARS-reactive antibody, CR3022, was assessed. 
CR3022 was able to broadly drive antibody effector functions, providing critical immune clearance 
at entry and upon egress. Using selectively engineered Fc variants, no protection was observed after 
administration of WT IgG1 in mice or hamsters. Conversely, the functionally enhanced Fc variant 
resulted in increased pathology in both the mouse and hamster models, causing weight loss in mice 
and enhanced viral replication and weight loss in the more susceptible hamster model, highlighting 
the pathological functions of Fc-enhancing mutations. These data point to the critical need for 
strategic Fc engineering for the treatment of SARS-CoV-2 infection.
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and antiinflammatories are under investigation (5, 6). In addition, anti–SARS-CoV-2 monoclonal thera-
peutics also have been proposed to control and clear the infection.
The coronavirus spike protein (S), found on the surface of  coronaviruses, is involved in viral attach-
ment and fusion (7). Treatment with monoclonal antibodies against SARS-CoV S protein has been shown 
to protect mice from viral pathogenesis (8). Delivery of  both neutralizing and non-neutralizing antibodies 
against the MERS virus afforded protection (9–11), highlighting the potential importance both of  block-
ade of  infection and targeted immune-mediated clearance of  the virus/virally infected cells in protection 
from infection. Likewise, both neutralization and antibody-dependent cellular cytotoxicity (ADCC) have 
been linked to protection in SARS-infected individuals (12) and animal models (13). Given the remarkable 
infectiousness of  SARS-CoV-2, with an estimated R0 approximately 2.5 (14–18), strategies to provide com-
plete protection from infection may require both blocking and postinfection eliminating-antibody functions 
for maximal immunity. However, data from SARS-CoV–immunized nonhuman primates pointed to the 
potential role of  neutralizing antibodies in enhancing disease, via the induction of  inflammatory respons-
es (19), suggesting that caution is warranted in the application of  monoclonal antibody therapeutics for 
SARS-CoV-2 treatment.
To begin to explore the potential immune-protective versus immunopathological role of  antibodies, we 
focused on an antibody derived from a SARS-CoV–infected individual, CR3022, that targets a conserved 
epitope of  the receptor binding domain (RBD) and that binds to the SARS-CoV-2 RBD (20). Because this 
cross-reactive antibody exhibits limited neutralization, despite binding to conserved determinants on the 
RBD (21), the antibody offered an opportunity to explore Fc-dependent effects on SARS-CoV-2 not con-
founded by neutralization. Moreover, given that CR3022 continues to bind to RBD even in the presence of  
angiotensin-converting enzyme 2 (ACE2) (20–22), CR3022 has the potential to confer eradication of  infect-
ed cells even in the setting of  high ACE2 secretion (23). Thus, here we coupled Fc functional profiling, Fc 
engineering, and in vivo profiling to examine the role of  Fc effector function on the response to SARS-
CoV-2 infection. Distinct Fc functional profiles resulted in enhancement of  disease, pointing to antibody 
mechanisms of  action that may be detrimental when developing antibody therapeutics against the virus.
Results
CR3022 drives innate immune activity against SARS-CoV-2. Although great effort is underway to identify potent 
neutralizing antibodies against SARS-CoV-2, it remains uncertain whether neutralization alone, particular-
ly in the upper respiratory tract, will be sufficient to provide complete protection against this highly infec-
tious pathogen. Instead, past studies in MERS infection suggest that additional antibody functions, beyond 
neutralization, track with protective immunity (13). Thus, the ability to clear virus or infected cells that 
escape restriction in the upper respiratory tract may be essential to fully prevent disease. Here we focused 
on a first-in-class monoclonal antibody, initially cloned from a SARS-CoV–infected individual, because of  
its ability to bind to a mutated neutralization-resistant form of  the SARS-CoV S1-RBD (22). CR3022 binds 
to both SARS-CoV and SARS-CoV-2, with a binding footprint that likely provides the antibody with the 
ability to bind broadly across SARS-CoV mutants, such as SARS-CoV-2, and to continue to bind in the 
setting of  ACE2 binding to the RBD (20, 21). However, whether this antibody was able to drive additional 
functions of  potential therapeutic utility remained unclear.
To begin, we confirmed the ability of  CR3022 to bind to SARS-CoV and SARS-CoV-2 S as well as 
SARS-CoV-2 RBD and related CoV spike proteins (Figure 1A). As expected, CR3022 bound tightly to 
the SARS-CoV S, against which it was cloned. The antibody also bound SARS-CoV-2 RBD and S. In 
contrast, CR3022 did not bind to the MERS S, highlighting the specificity of  this antibody for SARS-re-
lated viruses. Although it was able to bind to SARS-CoV-2 RBD and potently neutralize SARS-CoV in 
vitro (22), limited authentic SARS-CoV-2 neutralization was observed even at very high antibody con-
centrations (Figure 1B) as has been previously observed (21).
Emerging data point to significant differences across monoclonal antibodies in their ability to drive Fc 
effector functions (24). Both the stoichiometry and geometry of  binding have been implicated in modulating 
antibody effector function (25). Given the peculiar angle with which CR3022 interacts with the SARS-CoV-2 
RBD (21), we next examined the ability of  CR3022 to drive Fc effector function. CR3022 bound to SARS-
CoV-2 S was able to bind to Fc gamma receptors 2a and 3a (FcγR2a and FcγR3a) (Figure 1C), whereas no 
FcR binding was observed with the control EBOV-specific antibody (KZ52) bound to SARS-CoV-2 S, likely 
due to lack of  EBOV monoclonal binding to the SARS-CoV-2 antigen (25). Along the same lines, CR3022 
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was able to drive antibody-dependent cellular (monocyte) phagocytosis (ADCP), antibody-dependent NK 
cell activation (ADNKA, as measured by macrophage inflammatory protein 1b [MIP-1b] expression), anti-
body-dependent complement deposition (ADCD), and antibody-dependent neutrophil phagocytosis (ADNP) 
(Figure 1, D–G). Moreover, CR3022 was still able to drive antibody effector function, namely ADCP and 
ADCD, in the presence of  ACE2 (Figure 1, H and I). Thus, unlike neutralizing antibodies, many of  which 
compete with ACE2 binding, CR3022 may still drive antibody-effector clearance of  virus or infected cells 
even upon ACE2 upregulation following infection (26).
Comparison of  CR3022 and other SARS-CoV-2 monoclonals. To fully probe the therapeutic potential of  
CR3022, we compared the functional activity of  CR3022 with recently published (27) or discovered mono-
clonal antibodies specifically cloned from SARS-CoV-2–infected individuals. Specifically, the ability of  
CR3022 to mediate ADCP, NK activation, ADCD, and ADNP was compared with 2 neutralizing anti-
bodies (B38 and 0012C10) and 1 non-neutralizing antibody (0012E4) (Table 1). In addition, we used an 
EBOV-targeting antibody (KZ52) as a negative control. All SARS-CoV-2 RBD-targeting antibodies drove 
similar levels of  ADCP and ADNP (Figure 2, A and B), with CR3022 comparable to all other SARS-
CoV-2 monoclonals. Conversely, CR3022 drove slightly more NK activation, as represented by MIP-1b 
secretion (Figure 2C), and significantly more complement deposition (ADCD) compared with the other 3 
SARS-CoV-2 RBD-targeting antibodies (Figure 2D). Thus, CR3022 exhibited similar if  not superior anti-
body-effector function compared with neutralizing and other non-neutralizing antibodies. Moreover, given 
the emerging role for ADCD in providing vaccine-mediated protection in vivo (28), the ability of  CR3022 
to facilitate ADCD makes CR3022 an ideal candidate for potential therapeutic applications.
Fc engineering can tune CR3022 effector function. Although Fc effector functions have been linked to pro-
tection from MERS infection in mice (13), data have also emerged pointing to the potentially deleterious 
role of  Fc effector functions in enhancing SARS-CoV disease (19, 29, 30). Thus, using a simple Fc-engi-
neering approach where the variable domains of  CR3022 are swapped onto the Fc domain of  distinct Fc 
variants with previously defined point mutations known to alter antibody interactions with Fc receptors, we 
generated a small panel of  CR3022 Fc variants, able to selectively augment phagocytosis, NK cell function, 
and complement activity. Given clear overlap and concordance in human IgG1 performance across human 
and mouse effector functions (31), we focused on known mutations in human IgG1 and compared human 
and mouse Fc receptor binding as well as human antibody effector functions. These mutations in the CH2 
or CH3 of  the Fc of  IgG1 were previously identified to alter binding to FcγRs, resulting in enhancement 
or reduction of  Fc effector function. Specifically, 4 mutants were explored: a mutant able to enhance all Fc 
effector functions (EFTEA, ref. 32), 2 mutations known to enhance ADCC and ADCP (SDIE and SDIE-
SA, ref. 33), and a mutation that knocks out all Fc function (N297Q, ref. 34). To begin characterizing the 
function of  these variants, we analyzed the ability of  these mutants to bind both human FcγRs and mouse 
Fcγ receptors (mFcγRs) (Figure 3A). EFTEA showed similar binding to the human FcγRs as WT CR3022. 
SDIE exhibited slightly higher binding to the human FcγRs compared with WT, whereas SDIESA had a 
slight and selective reduction in binding to the human FcγR3A and FcγR3B. Conversely, the Fc-knockout 
mutation, N297Q, resulted in a near-complete loss of  Fc receptor binding.
Although the variants bound the mouse FcγRs with lower affinity than the human FcγRs, most vari-
ants retained considerable binding to mFcγR4, an activating receptor in mice that has been implicated 
in antibody effector function (35). In particular, SDIE exhibited the highest binding to the mouse FcγRs 
Figure 1. CR3022 drives effector function against SARS-CoV-2. (A) CR3022 was serially diluted and tested for its ability to bind the spike protein of dif-
ferent coronaviruses by ELISA (left). Data are represented as the OD450 values background subtracted from the reference OD570 value. Each dot represents 
the average of 2 replicates. The bar plot displays the EC50 for each antigen. MERS RBD and Ebola virus (EBOV) glycoprotein are not displayed because 
their respective EC50 was each infinite. The bars represent the average of 2 replicates, and the error bars represent the standard deviation. (B) CR3022 was 
serially diluted and preincubated with SARS-CoV-2 before adding to the virus and antibody to Vero E6 cells. Percentage neutralization was determined by 
the percentage reduction in plaque counts compared with a vehicle control. Data represent the means of triplicates and error bars represent the standard 
deviation. (C) CR3022 and a control EBOV-specific antibody binding to FcγR2a and 3a were evaluated using Luminex with a serial dilution of CR3022. The 
AUC was calculated for the MFI values. The bar represents the mean of 2 replicates. (D–G) CR3022 was evaluated for its ability to drive ADCP (D), NK activi-
ty (as measured by MIP-1b activity) (E), ADCD (F), and ADNP (G). For the line graphs (left), each dot represents the mean of 2 replicates. For the bar graphs, 
values are represented as the mean AUC of 8 serial dilutions run in replicate. The error bars for the dots and the AUC represent the standard deviation. For 
the before-after plot (E), each dot represents the activity of 1 donor after incubation with CR3022 or serum. Significance for NK activation (E) was deter-
mined by a Wilcoxon matched pairs signed rank test, *P < 0.05. (H and I) The ability of CR3022 and a control EBOV-specific antibody (KZ52) to drive ADCP 
(H) and ADCD (I) in the presence of ACE2 was analyzed. The bars indicate the average AUC of 8 serial dilutions run in 2 replicates. The error bars represent 
the standard deviation. Significance was determined by a 1-way ANOVA test followed by Tukey’s multiple-comparison test. *P < 0.05.
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compared with all other variants. Consistent with FcγR binding profiles, the EFTEA mutant exhibited 
enhanced pan-functionality, with a selective increase in ADCD (Figure 3E). Conversely, both SDIE and 
SDIESA exhibited enhanced ADCP and ADNP but not ADCD activity, with SDIE exhibiting enhanced 
ADNP compared with the other mutants (Figure 3, C–E). Finally, SDIESA exhibited the highest ADCP 
activity and NK activation, as measured by MIP-1b expression, of  the group (Figure 3, B and C), high-
lighting the distinct functional profiles of  each of  the modifications. Although some residual binding was 
noted for N297Q on FcγR2A (Figure 3A), near-complete loss of  antibody function was observed with 
this Fc variant (Figure 3, B–E), driving effector function at a similar level as the EBOV-specific control 
antibody, underscoring the dominant silencing effect of  this mutation. Overall, these data highlight a 
range of  functional variation across the Fc variants, enabling the down-selection of  3 variants for in vivo 
analysis: WT, Fc-knockout (Fc-KO), and pan-functional SDIE variant, which exhibited the highest bind-
ing to mouse FcγRs (Figure 3A).
Dissecting therapeutic Fc signals of  protection. Using these down-selected Fc variants, we next aimed 
to probe the role of  Fc effector function in protection from infection and disease (36). BALB/c mice 
were treated 12 hours following SARS-CoV-2 infection to probe for therapeutic protective Fc functions. 
Specifically, BALB/c mice were infected with 105 PFU of  mouse-adapted SARS-CoV-2 i.n.; treated 
with 200 μg of  the WT, Fc-KO, or control antibody or 100 μg of  the Fc-enhanced antibody i.p.; and 
monitored for 2 days for lung viral titer and weight loss, with 5 mice per group (Figure 3, F and G).
Strikingly, slightly higher, but nonsignificant, differences were observed in viral replication using the WT 
CR3022 IgG1 compared with the control antibody and the WT antibody (Figure 3G). Moreover, reduction 
in viral load was observed with the Fc-enhanced CR3022 variant (Figure 3G). However, significant weight 
loss occurred in both WT and Fc-enhanced variant-treated mice and minimal to no weight loss in mice treat-
ed with the Fc-KO variants (Figure 3G). Thus, while the WT CR3022 IgG1 and the Fc-enhanced CR3022 
variants showed divergent virologic effects, both variants led to enhanced pathology. The disconnect between 
viral load and weight loss for the Fc-enhanced CR3022 antibody raised the possibility that the Fc-enhanced 
variant may have pathological consequences.
To further understand the role of  Fc-enhanced pathology, we next tested the therapeutic benefit of  
the CR3022 variants in a more pathological model of  SARS-CoV-2 infection (37, 38). Syrian golden 
hamsters are highly susceptible to SARS-CoV-2 infection and develop severe infection after challenge. 
Thus, using this model, we assessed the panel of  Fc-engineered monoclonals. Hamsters were chal-
lenged i.n. with 106 PFU/mL (107 TCID50) of  SARS-CoV-2, and 1 day after infection, treated with 5 
mg/kg IgG1, Fc-enhanced, Fc-KO, or a control antibody, with 5 hamsters per group. Weight was mon-
itored daily, and lung viral titers were determined 3 days after infection (Figure 4, A and B). Similar 
to the results observed in the mouse model (Figure 3G), the WT CR3022 had no impact on viral load 
compared with control antibody–treated animals (Figure 4A). In contrast to mice, hamsters did not 
experience any benefit from the Fc-KO antibody (Figure 4A), likely due to the more severe nature of  the 
infection in this model. Conversely, hamsters treated with the Fc-enhanced CR3022 exhibited increased 
viral load in the lung and increased weight loss (Figure 4, A and B). Despite the viral load disparity 
across the mice and hamsters, both models exhibited increased weight loss upon treatment with the 
Fc-enhanced CR3022 (Figure 3G and Figure 4B), suggesting similar host responses to the Fc-enhanced 
monoclonal. Thus, collectively, these data point to the critical importance of  balancing Fc effector func-
tion to temper pathology in susceptible populations.






The table lists the neutralizing capacity of a panel of monoclonal antibodies that bind to the SARS-CoV-2 RBD, with 
B38, 0012C10, and 0012E4 cloned from infected individuals. B38 and 0012C10 are able to neutralize the virus, whereas 
CR3022 and 0012E4 have limited to no neutralizing capacity.
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Discussion
Given the rapid spread of  SARS-CoV-2, therapeutics are urgently needed to not only prevent but also treat 
COVID-19. Among the strategies, passive transfer of  monoclonal antibodies, which are able to both drive 
directed antiviral activity and also tune the immune system, represent an ideal class of  therapeutics, poten-
tially suited for both prevention and therapy. However, emerging data pointing to the possibility of  antibody 
enhancement of  disease following vaccination against SARS-CoV have raised the importance of  carefully 
considering the role of  the antibody Fc in SARS-CoV-2 therapeutic design. Here we focused on a first-in-class 
cross-SARS monoclonal antibody, CR3022, which interacts with a conserved region of  the RBD. Although 
the antibody itself  was highly functional, even in the presence of  ACE2 (Figure 1), additional Fc engineering 
was performed, allowing us to gauge the therapeutic benefits of  Fc activity (Figure 3). Surprisingly, the Fc-en-
hanced CR3022 antibody conferred some viral control when administered in mice but was accompanied by 
significant morbidity in both mice and hamsters, potentially by promoting an inflammatory response.
Past reports have shown some evidence of antibody-dependent enhancement (ADE) of SARS infection. 
Although many of these studies rely on in vitro systems with high levels of virus, diluted serum, or nonfunc-
tional antibodies (39, 40), a more recent study in nonhuman primates pointed to a disease-enhancing role of  
modified vaccinia Ankara-induced SARS-CoV neutralizing antibodies (19). In vitro data suggested that despite 
the neutralizing activity of the vaccine-induced antibodies, ADE in SARS infection was caused by FcγR2-me-
diated activation of myeloid cells (41, 42). ADE is most well documented during Dengue virus infection, in 
which previous infection places an individual at risk, upon reinfection, to develop Dengue hemorrhagic fever/
Dengue shock syndrome (DHF/DSS). This disease enhancement is thought to occur due to the presence of  
antibodies directed at a different Dengue serotype. Specifically, subneutralizing levels of preexisting antibod-
ies to one serotype that have limited cross-reactive neutralizing capacity to a second serotype are enriched in 
children who develop DHF/DSS following exposure to a new serotype of the virus (43). Moreover, in vitro, 
low levels of neutralizing antibodies have been shown to facilitate viral entry into myeloid cells following FcγR 
engagement, resulting in enhanced infection and consequent inflammation (44). However, it is critical to note 
that limited evidence exists for SARS-CoV-2 infection of myeloid cells (45, 46). Instead, SARS-CoV-2 target 
Figure 2. CR3022 possesses comparable Fc activity to neutralizing and non-neutralizing SARS-CoV-2 monoclonal antibodies. (A–D) CR3022 was 
tested for its ability to drive ADCP (A), ADNP (B), NK cell activation (C), or ADCD (D) compared with other SARS-CoV-2 RBD-targeting monoclonals. 
For the line graphs, each dot represents the mean of 2 replicates. For NK cell activation, 3 donors were used. For the bar graphs, the values are 
represented as the AUC of serial dilutions. The dotted line represents the average AUC value for the control EBOV-targeting antibody (KZ52). The 
error bars represent the standard deviation between the replicates. Significance was determined by an ordinary 1-way ANOVA followed by Tukey’s 
multiple-comparison test. *P < 0.05, ****P < 0.0001.
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cells do not express FcγR, and thus enhanced infection is unlikely to occur in the same manner as for Den-
gue viral infection. Conversely, SARS-CoV-2 target cells do express the neonatal Fc receptor, FcRn (47, 48). 
Whether enhancement can be caused by FcRn remains unclear. Yet, enhanced FcγR engagement may deliver 
virus preferentially to endosomal compartments in phagocytes, resulting in viral sensing and inflammatory 
responses, that may then lead to inflammation, cellular recruitment, and potential pathology. Thus, antibodies 
in SARS-CoV-2, unlike Dengue viral infection, may cause enhanced inflammation rather than enhanced infec-
tion. Importantly, here both FcγR-engaging antibodies drove pathology in both mice and hamsters but showed 
differences in viral loads. These data point to a disconnect between viral load and pathogenesis that may be 
dissected in the future with in-depth immunohistopathological studies across the 2 animal models.
Figure 3. CR3022 can be enhanced through Fc engineering. (A) Each CR3022 variant was analyzed for its ability to bind the human FcγR2a, FcγR2b, 
FcγR3a, and FcγR3b or the mouse FcγR2b, FcγR3, and FcγR4 by Luminex. Each bar represents the average MFI and error bars show standard devi-
ation. (B) The CR3022 variants were analyzed for their ability to drive NK activation, as measured by MIP-1b activity. The bar graphs represent the 
average of 3 donors, and the error bars represent the standard deviation. For AUC, significance was determined by an ordinary 1-way ANOVA followed 
by Tukey’s multiple-comparison test. *P < 0.05. (C–E) The CR3022 variants were evaluated for their ADCP (C), ADNP (D), and ADCD (E) activity. The 
dots on the line graph represent the average of 2 replicates. The bar graphs represent the average AUC of 8 serial dilutions run as replicates, and the 
error bars represent the standard deviation. For AUC, significance was determined by an ordinary 1-way ANOVA followed by Tukey’s multiple-com-
parison test. *P < 0.05. (F and G) BALB/c mice (5 per group) were treated with a CR3022 variant or control therapeutically. Lung viral titers were 
determined 2 days postinfection (dpi) (F), and weight was monitored daily (G). For viral titer (F), significance was determined by an ordinary 1-way 
ANOVA followed by Tukey’s multiple-comparison test. *P < 0.05. For weight (G), significance was determined by an ordinary 1-way ANOVA followed 
by Tukey’s multiple-comparison test. *P < 0.05, **P < 0.01, between the respective antibody, indicated by the color of the asterisk, and the CR3022 
WT. For weight (G), each dot represents a mouse, and the error bars represent the standard deviation.
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It is critical to note that antibodies elicited by infection and vaccine platforms or monoclonal 
antibodies do not have the same Fc binding profiles as those induced by modified vaccinia Ankara 
(MVA) vaccination that was previously associated with SARS-CoV–enhanced disease in macaques 
(49). Importantly, distinct Fc binding profiles can be generated following infection and vaccination, 
driven by altered Fc subclass selection and Fc glycosylation (49). Moreover, previous studies have 
clearly illustrated striking differences in antibody functional profiles across MVA-, pox virus–, adeno-
virus-, and protein-based immunization strategies (50). Thus, it is plausible that polyclonal pools of  
antibodies, with neutralizing properties and balancing Fc receptor binding profiles via balanced Fc gly-
cosylation, may provide protection in the absence of  disease. Along these lines, recent vaccine studies 
point to a positive predictive role of  polyclonal Fc recruiting directed at both the whole spike and RBD 
of  SARS-CoV-2 (28, 51). Similarly recent monoclonal therapeutic studies with neutralizing WT IgG1 
demonstrate limited evidence of  disease in humans (52).
Despite the significant loss of  most Fc effector functions in the Fc-KO variant (Figure 3), this variant 
retained low-level binding to human FcγR2A, involved in phagocytosis in humans (53). This remaining Fc 
receptor binding may have contributed to low but sufficient levels of  immune complex–based activation 
in the susceptible hamster model, where even the Fc-KO variant drove weight loss. These data point to 
the ultrasensitive nature of  the hamster model. Although mice exhibit more attenuated disease, hamsters 
suffer highly pathological responses to SARS-CoV-2 (37). Whereas the Fc-KO exhibited reduced viral and 
no weight loss in the mice, the administration of  the Fc-enhanced variant resulted in pathology. Con-
versely, the more susceptible hamster model showed no benefit with any of  the Fc variants and instead 
exhibited the same enhanced pathology with the Fc-enhanced. Thus, Fc enhancement may represent a 
liability across the disease spectrum. However, it is critical to note that many distinct Fc modifications 
can be utilized to drive enhanced biological activity. Although the SDIE mutation used here improved all 
measured Fc effector functions, other mutations exist that selectively improve NK cell activity, monocyte 
phagocytosis, neutrophil activation, or complement deposition, offering potentially more precise mecha-
nisms to control infection. Moreover, recent vaccine correlates analysis in nonhuman primates highlighted 
the complementary activity of  monocyte phagocytosis and complement in viral control (28, 51). Whether 
these functions alone may selectively clear the virus and prevent inflammation and pathology remains 
unclear but could provide critical clues for the strategic engineering of  monoclonal antibodies to maximize 
protection and minimize pathology.
Figure 4. Increased Fc function causes enhancement of disease in vivo. Hamsters (5 per group) were challenged with 
SARS-CoV-2 and treated with a CR3022 variant or control antibody 1 dpi. Lung viral titers were determined 3 dpi (A), and 
weight was monitored daily (B). For viral titers (A), significance was determined by an ordinary 1-way ANOVA followed by 
Tukey’s multiple-comparison test. **P < 0.01, ***P < 0.001. For weight (B), significance was determined by 2-way ANOVA 
test followed by Tukey’s multiple-comparison test. *P < 0.05 between the respective antibody and the CR3022 WT. For 
weight (B), each dot represents the average of 5 hamsters, and the error bars represent the standard deviation.
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As the number of  COVID-19 cases rise globally, new therapies are urgently needed to treat this highly 
infectious virus. Here, we characterized the therapeutic functions of  the monoclonal antibody CR3022 that 
binds to a conserved site on the RBD that is not fully blocked in the presence of  ACE2, offering therapeutic 
benefit even after infection has been initiated. The data presented here show no effect of  CR3022 as a WT 
IgG1. Surprisingly, both the Fc-enhanced and Fc-silenced variants of  CR3022 showed an antiviral benefit in 
mice but resulted in dichotomous treatment-associated pathology. Interestingly, the same pathological phe-
notype was observed in hamsters with the Fc-enhanced variant, highlighting the consistent disease-enhanc-
ing phenotype of  highly functional non-neutralizing monoclonal variants. With the rapid discovery of  novel 
neutralizing antibodies and pan–cross-reactive CoV antibodies, coupled to rapid Fc engineering, enabling the 
potential to deeply profile the involvement of  all Fc receptors (including FcγR1, FcγR2a, FcγR2b, FcγR3a, 
FcγR3b, FcRn, as well as noncanonical Fc receptors) and the generation of  functionally optimized antibod-
ies with appropriate half-lives, the development of  therapeutics with the highest clinical benefit is possible.
Methods
Cell lines. THP-1 cells, originally isolated from a 1-year-old male human (ATCC), were maintained 
in RPMI supplemented with 10% fetal bovine serum, l-glutamine, HEPES, penicillin/streptomycin, and 
0.01% β-mercaptoethanol. Vero E6 cells, from BEI Resources, National Institute of  Allergy and Infectious 
Diseases (NIAID) NIH: VERO C1008 (E6), African green monkey kidney, Working Bank NR-596, were 
maintained in humidified incubators at 37°C and 5% CO2 in Dulbecco’s modified Eagle medium (DMEM) 
with GlutaMAX and sodium pyruvate supplemented with 10% (v/v) certified US-origin heat-inactivated 
fetal bovine serum (HI-FBS).
Viruses. SARS-CoV-2 USA-WA1/2020 (54) was propagated on Vero E6 cells in DMEM supplemented 
with 2% HI-FBS, GlutaMAX, sodium pyruvate, nonessential amino acids, and antibiotic-antimycotic. At 
62 hours, the supernatant was harvested and clarified by centrifugation. The final concentration of  HI-FBS 
was diluted to 10% (v/v) prior to cryopreservation at –80°C. Final passage was VERO+3, Vero E6+2 (lot 
NSU-V004). The sequence of  this stock was identical to the published reference consensus sequence (54).
For in vivo studies, a recombinant SARS-CoV-2 mouse-adapted variant was constructed by introduction 
of  2 amino acid changes in the ACE2 binding pocket. Virus stocks were grown on Vero cells and titered by 
plaque assay as previously described by our group (36).
Animals. Female 12-month-old BALB/c mice were obtained from Envigo (strain 047). All animal work 
was approved by Institutional Animal Care and Use Committee at University of North Carolina at Chapel 
Hill. Syrian golden hamsters, 6–7 weeks old, were from and maintained at University of Texas Medical Branch.
Plasmid design. To create the CR3022 variants, gene blocks were designed containing the Fc domain of  
IgG1 and previously defined, individual Fc point-mutant backbones with known differences in binding to 
Fc receptors and functional differences (32–34). These Fc domains were cloned into individual pUC donor 
plasmids. In addition, 3 pUC plasmids encoding the variable heavy chain, a furin P2A sequence, or the 
variable light chain were designed surrounded by BsaI sites. In addition to the 4 pUC plasmids, a destina-
tion vector was cloned with an IL-2 secretion signal, the suicide gene ccdB surrounded by BsaI sites, and 
the kappa light chain sequence. The 4 pUC donor plasmids and the destination vector were combined in a 
single digestion-ligation reaction, using Golden Gate cloning, to create full IgG molecules with the same 
CR3022 antigen-binding (Fab) domain but different Fc domains.
Protein expression and purification. The RBD (residues 319–529) of  SARS-CoV-2 S protein (Gen-
Bank: MN975262.1) were subcloned into a pVRC vector with a C-terminal SBP-tag.
The CR3022 (GenBank: DQ168569 and DQ168570), B38 (27), and 0012C10 and 0012E4 antibodies 
(provided in-house) were produced in 293F suspension cells grown in FreeStyle 293 Expression media 
(Gibco, Thermo Fisher Scientific). Cells were transfected with Polyethylenimine (PEI; Polysciences) at 
1 μg/μL in a ratio of  3 μg PEI to 1 μg DNA. Supernatants were harvested 5 days posttransfection, and 
antibody was purified using protein G magnetic beads (MilliporeSigma). For in vitro analysis, KZ52 (May-
flower Bioscience, 0260-001) was used as a negative control.
ELISA. ELISA plates were coated with 50 ng/well of  antigen in PBS overnight at 4°C on a shaker at 
low speed. The next day, plates were washed 5 times with PBS-0.05% Tween-20 (PBST) and blocked in 5% 
BSA in PBS for 2 hours at room temperature on a shaker at low speed. Plates were washed 5 times with 
PBST, and 5-fold serially diluted antibody was added and incubated for 2 hours at room temperature on a 
shaker at low speed. After the incubation, plates were washed with PBST and anti–human IgG1–HRP was 
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added for detection. Plates were incubated for 1 hour at room temperature on a shaker at low speed. Plates 
were washed with PBST. The ELISA was developed with the addition of  TMB (Invitrogen, Thermo Fisher 
Scientific). The reaction was stopped with 1 M H2SO4. Signal reading was carried out at 450 nm (reference 
wavelength of  570). Data were reference value and background corrected.
ADCP assay. The ADCP assay was adapted from Ackerman et al. (55). Briefly, antigen was biotinylat-
ed using sulfo-NHS (N-hydroxysulfosuccinimide, Pierce, Thermo Fisher Scientific, A39269) LC-LC biotin, 
coupled to yellow-green fluorescent Neutravidin 1 μm beads (Invitrogen, Thermo Fisher Scientific, F8776) 
for 2 hours at 37°C and washed 3 times in 0.1% BSA in PBS. The coupled beads were resuspended to a final 
volume of 10 μg/mL. A total of 10 μL/well of coupled beads were added to 96-well plates with 100 μL/well 
of antibodies at a concentration of 5 μg/mL, 1 μg/mL, 0.2 μg/mL, and 0.04 μg/mL for 2 hours at 37°C to 
form immune complexes. After incubation, the immune complexes were spun down and the supernatant was 
removed. THP-1 cells (ATCC) were added at a concentration of 2.5 × 104 cells/well and incubated for 18 hours 
at 37°C. After incubation, the plates were spun down, the supernatant was removed, and cells were fixed with 
4% PFA for 20 minutes. Fluorescence was acquired with an Intellicyt iQue. Phagocytic score was calculated 
using the following formula: (percentage of FITC+ cells × the geometric MFI of the FITC+ cells)/10,000.
ADNP assay. The ADNP assay was adapted from Karsten et al. (56). Antigens were coupled to beads 
and immune complexes were formed as described for ADCP. Neutrophils were isolated from freshly drawn 
whole blood. Erythrocytes were lysed with ammonium-chloride potassium lysis buffer (150 mM NH4Cl, 10 
mM KHCO3, 0.1 mM Na2 EDTA, pH 7.4), and leukocytes were separated out by centrifugation, 500g for 
5 minutes at room temperature. Leukocytes were washed with cold PBS, resuspended in R10, and added to 
plates at a concentration of  5 × 104 cells/well. The plates were incubated for 1 hour at 37°C. The neutrophil 
marker CD66b (Pacific Blue–conjugated anti-CD66b; BioLegend, 305112) was used to stain cells. Cells were 
fixed for 20 minutes in 4% paraformaldehyde (PFA). Fluorescence was acquired with an Intellicyt iQue, and 
the phagocytic score was calculated as described for ADCP.
ADCD assay. The ADCD assay was adapted from Fischinger et al. (57). Antigen was coupled to red fluo-
rescent Neutravidin 1 μm beads (Invitrogen, Thermo Fisher Scientific, F8775) as described for ADCP. Immune 
complexes were formed by incubating 10 μL of coupled beads with 50 μL of antibody at concentrations of  
50 μg/mL, 10 μg/mL, 2 μg/mL, and 0.4 μg/mL for 2 hours at 37°C. Plated were spun down, and immune 
complexes were washed with PBS. Lyophilized guinea pig complement (Cedarlane, CL4051) was resuspended 
in 1 mL of cold water, diluted 1:50 in GVB++ (gelatin veronal buffer and additional Ca2+ and Mg2+, Boston 
BioProducts, IBB-300X), and added to the immune complexes. The plates were incubated for 20 minutes at 
37°C, and the reaction was stopped by washing the plates twice with 15 mM EDTA in PBS. To detect comple-
ment deposition, plates were incubated with fluorescein-conjugated goat anti–guinea pig complement C3 (MP 
Biomedicals, 0855385) for 15 minutes in the dark. Fluorescence was acquired with an Intellicyt iQue.
ADNKA (NK activation). Human NK cells were isolated from buffy coats using RosetteSep NK cell enrich-
ment kit (StemCell Technologies) and Ficoll separation. The isolated NK cells were rested overnight at 1.5 
× 106 cells/mL in IL-15 at 37°C. ELISA plates were coated with antigen at 300 ng/well and incubated for 2 
hours at 37°C. Plates were blocked with 5% BSA in PBS overnight at 4°C. The next day, 100 μL of antibodies, 
at a concentration of  5 μg/mL, were added to the plates. Plates were incubated for 2 hours at 37°C to form 
immune complexes. After the incubation, NK cells were added to the plates at 5 × 104 cells/well in R10 sup-
plemented with anti-CD107a PE-Cy5, Brefeldin A (MilliporeSigma, B7651-5MG), and GolgiStop (BD Bio-
sciences, 555802). Plates were incubated for 5 hours at 37°C. Following the incubation, NK cells were stained 
for the surface markers with anti-CD56 PE-Cy7, anti-CD16 APC-Cy7, and anti-CD3 Pacific Blue (BD Biosci-
ences, 557747, 557758, 558124). NK cells were fixed and permeabilized with Fix&Perm cell permeabilization 
kit (Invitrogen, Thermo Fisher Scientific). Cells were incubated with anti–MIP-1β PE and anti–IFN-γ FITC 
(BD Biosciences, 550078, 340449) to stain for intracellular markers. Cells were acquired on an Intellicyt iQue.
FcR binding. A multiplex assay was used to determine FcR binding as described in Brown et al. (58, 
59). A 2-step carbodiimide reaction was used to couple antigen to Magplex Luminex beads. Beads were 
activated for 30 minutes at room temperature using 100 mM monobasic sodium phosphate, pH 6.2, with 
5 mg/mL sulfo-NHS and 5 mg/mL ethyl dimethylaminopropyl carbodiimide hydrochloride. Beads were 
then washed with 50 mM 2-(N-Morpholino)ethanesulfonic acid (MES), pH 5.0, and incubated with 25 
μg of  antigen in 50 mM MES, pH 5.0, for 2 hours on a rotator. The coupled beads were blocked in Block-
ing Buffer (PBS, 0.1% BSA, 0.02% Tween-20, 0.05% Azide, pH 7.4). After blocking, coupled beads were 
washed in PBS-Tween, resuspended in PBS, and stored at 4°C.
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For the detection of  FcR binding, FcRs with an AviTag were biotinylated using a BirA500 kit (Avidity) 
per the manufacturer’s instructions. Coupled beads were diluted to a concentration of  100 microspheres per 
antigen/μL in 0.1% BSA in PBS. Antibodies were serially diluted in 0.1% BSA in PBS; mixed with diluted 
beads in a black, clear-bottom, 384-well plate; and incubated at 4°C for 16 hours, shaking at 900 rpm. After 
the incubation, plates were washed with 0.1% BSA in PBS. FcRs were incubated with streptavidin-PE 
(Prozyme, PJ31S) for 10 minutes. PE-labeled FcRs were added to plates and incubated for 1 hour at room 
temperature on a shaker. Plates were washed with 0.1% BSA in PBS and resuspended in Qsol Buffer (Intel-
licyt). Fluorescence was acquired on the Intellicyt iQue.
In vitro plaque reduction neutralization assay. The day prior to assay, VeroE6 cells were seeded to a 
density of  8 × 105 cells/well in 6-well plates. SARS-CoV-2 was diluted in DMEM with GlutaMAX and 
sodium pyruvate supplemented with 1× antibiotic-antimycotic and 2% HI-FBS to 1000 PFU/mL (tar-
get 100 PFU per well). Antibody was serially diluted in Dulbecco’s PBS, and an equal volume of  dilut-
ed SARS-CoV-2 was added, mixed, and incubated for 1 hour at 37°C before plating on 6-well plates 
(200 μL in triplicate). Following a 1-hour incubation at 37°C with periodic rocking, they were overlaid 
with a 1:1 mixture of  2.5% (w/v) Avicel RC-591 (provided by DuPont Nutrition & Health) prepared in 
distilled water and 2× Temin’s Modified Eagle Medium (Thermo Fisher Scientific) supplemented with 
10% HI-FBS, 2× GlutaMAX, and 2× antibiotic-antimycotic. Following a 2-day incubation at 37°C and 
5% CO2, plates were fixed with 10% neutral buffered formalin for removal from biocontainment and 
stained with a solution of  0.2% Gentian Violet and 10% neutral buffered formalin. Plates were rinsed 
under water and plaques were enumerated. Percentage neutralization was calculated from vehicle/
virus-only control wells.
In vivo challenge. Female 12-month-old BALB/c mice were treated prophylactically (12 hours before 
infection) or therapeutically (12 hours after infection) with 200 μg or 100 μg of  antibody through 
the intraperitoneal route. Each group contained 5 mice. Mice were challenged i.n. with 105 PFU of  
mouse-adapted SARS-CoV-2, representing 0.69 × 105 TCID50, which falls clearly in the range of  viral 
loads observed in hospitalized patients (60). Weight was monitored on days 0, 1, and 2 after infec-
tion. Mice were sacrificed 2 days after infection, and lung viral titer was determined by plaque assay. 
Although the Fc variants experience different half-lives in vivo, the studies performed here were short; 
but half-life should be considered for longer studies.
Adult hamsters were microchipped a day prior to experimental challenge. On day 0, hamsters were 
anesthetized with ketamine/xylazine and challenged with SARS-CoV-2 by the i.n. route using a 107 
TCID50 (or 10
6 PFU/mL) dose in a total volume of  100 μL. The final challenge dose was 104 PFU dilut-
ed in sterile PBS. Body weight and body temperature were measured each day, starting at day 0. On day 
1 postchallenge (1 dpc) hamsters were treated with 5 mg/kg of  monoclonal antibodies diluted in 0.5 mL 
of  sterile PBS via the intraperitoneal (i.p.) route. The control group got an equal volume of  sterile PBS 
via the same i.p. route. On 3 dpc all animals were sacrificed. At necropsy, lungs were harvested for all 
groups. Left lungs were fixed with 10 volumes of  fresh 10% formalin; right lungs were frozen in 5 mL 
lysogeny broth from Thermo Fisher Scientific for viral load analysis. Tissue sections were homogenized 
in bead beater tubes (Thomas Scientific) and weighed, and supernatants were titrated per standard pro-
tocol. Briefly, 100 μL of  a 10× dilution of  supernatants was incubated in 96-well plates for 1 hour, and 
supernatants were replaced by methyl cellulose overlay and incubated for 3 days at 5% CO2 and 37°C. 
Plates were fixed with formalin and removed from the biosafety level 4 facility, after which the plates 
were inactivated and immunostained, and the plaques were counted to obtain viral titers.
Statistics. All data were visualized and analyzed in GraphPad Prism. Nonparametric tests were 
performed as described in figure legends. Where applicable, significance was determined as *P < 0.05, 
**P < 0.01, ***P < 0.001.
Study approval. Primary human innate immune cells were isolated from fresh peripheral blood samples 
collected by the Massachusetts General Hospital (MGH) blood bank. All subjects provided informed con-
sent, and the study was approved by the MGH Institutional Review Board. All subjects were older than 18 
years of  age, and samples were deidentified prior to use.
All mouse work was approved by the Institutional Animal Care and Use Committee at the University 
of  North Carolina at Chapel Hill. The animal protocols for the hamster models were approved by the Insti-
tutional Animal Care and Use Committee of  the University of  Texas Medical Branch.
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